Remote Ischemic Conditioning in STEMI to Decrease Infarct Size

A Multi-center Randomized Trial of Remote Ischemic Conditioning to Reduce Infarct Size in Patients With an ST-Elevation Myocardial Infarction

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03930589

Acronym

RemCon-STEMI

Enrollment

251

Registered

2019-04-29

Start date

2013-11-08

Completion date

2018-11-26

Last updated

2019-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

CAD, STEMI

Brief summary

Following acute STEMI patients may have significant myocardial damage and subsequent heart failure. There is currently conflicting data regarding the benefit of remote ischemic conditioning to decrease the magnitude of infarction. Remote ischemic condition is a process where by repetitive intermittent limb ischemia is used to decrease the magnitude of myocardial damage caused by coronary artery occlusion and the subsequent reperfusion injury in STEMI patients. RemCon-STEMI is a multicenter randomized trial to test the impact of remote ischemic conditioning in acute STEMI.

Interventions

PROCEDURERemote Ischemic conditioning

BP cuff inflation for 5 min and deflation for 5 mins with 4 cycles

OTHERStandard of care

Standard of care

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Outcomes Assessor)

Masking description

Patient outcomes and markers blinded to randomization arm

Intervention model description

Remote ischemic condition versus standard of care

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

Patients presenting with STEMI within 6 hours of symptom onset and: 1. Are expected to receive reperfusion therapy with either fibrinolysis or primary PCI. 2. Documented informed consent (verbal)

Exclusion criteria

1. Cardiogenic shock 2. History of anatomical deformity or vascular complication that limit ability to conduct remote ischemic preconditioning

Design outcomes

Primary

Measure	Time frame	Description
Composite of all cause death	90 days	all cause death, cardiogenic shock or chf through 90 days

Secondary

Measure	Time frame	Description
long term survival	up to 1 year	survival
myocardial infarction size	within 72 hours of hospital admission	mi size using peak elevation of cardiac biomarkers
ECG infarct size	with 10 days or hospital discharge whichever occurs first	QRS score on baseline and discharge ECGS
Reperfusion	within 24 hours of admission to hospital	ST segment resolution 30 minutes post PCI

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 14, 2026